[Federal Register Volume 84, Number 248 (Friday, December 27, 2019)]
[Notices]
[Page 71474]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-27954]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-552]


Importer of Controlled Substances Application: Myoderm

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before January 27, 2020. 
Such persons may also file a written request for a hearing on the 
application on or before January 27, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on October 14, 2019, Myoderm, 48 East Main Street, 
Norristown, Pennsylvania 19401-4915 applied to be registered as an 
importer of the following basic classes of controlled substances:

------------------------------------------------------------------------
          Controlled substance               Drug code       Schedule
------------------------------------------------------------------------
Amphetamine.............................            1100              II
Lisdexamfetamine........................            1205              II
Methylphenidate.........................            1724              II
Nabilone................................            7379              II
Oxycodone...............................            9143              II
Hydromorphone...........................            9150              II
Hydrocodone.............................            9193              II
Morphine................................            9300              II
Oxymorphone.............................            9652              II
Fentanyl................................            9801              II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances for 
clinical trials, research, and analytical purposes. Approval of permit 
applications will occur only when the registrant's business activity is 
consistent with what is authorized under 21 U.S.C. 952(a)(2). 
Authorization will not extend to the import of FDA approved or non-
approved finished dosage forms for commercial sale.

    Dated: November 13, 2019.
William T. McDermott,
Acting Assistant Administrator.
[FR Doc. 2019-27954 Filed 12-26-19; 8:45 am]
 BILLING CODE 4410-09-P